Clinical use of blinatumomab for B-cell acute lymphoblastic leukemia in adults

Therapeutics and Clinical Risk Management

Volumn 12, Issue , 2016, Pages 1301-1310

  Lee, Kum Ja ^a   Chow, Vivian ^a   Weissman, Ashley ^a   Tulpule, Sunil ^b   Aldoss, Ibrahim ^c   Akhtari, Mojtaba ^d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Raritan Bay Medical Center   (United States)

^c Raritan Bay Medical Center ^*  (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

ALL; BiTE; Blincyto; Relapsed refractory

Indexed keywords

BLINATUMOMAB;

ABNORMAL LABORATORY RESULT; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ADULT DISEASE; ANTINEOPLASTIC ACTIVITY; B CELL LEUKEMIA; CANCER CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM DISEASE; CYTOKINE RELEASE; CYTOPENIA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SYNTHESIS; HUMAN; IMMUNOPHARMACOLOGY; IMMUNOTOXICITY; INFECTION; LIVER TOXICITY; MULTICENTER STUDY (TOPIC); NEUROTOXICITY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; TUMOR LYSIS SYNDROME;

EID: 84984870844     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S84261     Document Type: Review

References (26)

1. Jabbour EJ, Faderl S, Kantarjian HM.Adult acute lymphoblastic leukemia.Mayo Clin Proc.2005;80:1517-1527.
2. National Cancer Institute.SEER cancer statistics review, 1975-2011: Leukemia, annual incidence rates (acute lymphocytic leukemia); Updated 2014.Available from: http://seer.cancer.gov/csr/1975_2011.Accessed January 19, 2016.
3. American Cancer Society.Cancer Facts and Figures, 2016.Atlanta, GA: American Cancer Society; 2016.Available from: http://www.cancer.org/research/cancerfactsstatistics.Accessed January 19, 2016.
4. National Cancer Institute.SEER cancer statistics review, 1975-2011: Overview, median age at diagnosis; 2014.Available from: http://seer.cancer.gov/csr/1975_2011/.Accessed January 19, 2016.
5. NCCN Clinical Practice Guidelines in Oncology: Acute Lymphoblastic Leukemia.National Comprehensive Cancer Network.Version 1.2016.Available from: https://www.nccn.org/professionals/physician_gls/f_guidelines.asp.Accessed April 25, 2016.
6. Gökbuget N, Hoelzer D.Treatment of adult acute lymphoblastic leukemia.Semin Hematol.2009;46:64-75.
7. Bassan R.Adult acute lymphoblastic leukaemia.Crit Rev Oncol Hematol.2004;50:223-261.
8. Virchis A, Koh M, Rankin P, et al.Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndrome.Br J Haematol.2004;124(1):26-32.
9. Bassan R, Hoelzer D.Modern therapy of acute lymphoblastic leukemia.J Clin Oncol.2011;29(5):532-543.
10. FDA approves Blincyto to treat a rare form of acute lymphoblastic leukemia.FDA News Release.Silver Spring, MD: Food and Drug Administration; December 3, 2014.
11. Nagorsen D, Kufer P, Baeuerle PA, Bargou R.Blinatumomab: A historical perspective.Pharmacol Ther.2012;136:334-342.
12. Klinger M, Brandl C, Zugmaier G, et al.Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.Blood.2012;119(26):6226-6233.
13. Hoffmann P, Hofmeister R, Brischwein K, et al.Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct.Int J Cancer.2005;115(1): 98-104.
14. Zugmaier G, Topp MS, Alekar S, et al.Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia.Blood Cancer J.2014;4:244.
15. Topp MS, Gökbuget N, Zugmaier G, et al.Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.J Clin Oncol.2014;32(36): 4134-4140.
16. Blincyto® (Blinatumomab) [package insert].Thousand Oaks, CA: Amgen; 2014.
17. Topp MS, Kufer P, Gökbuget N, et al.Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.J Clin Oncol.2011;29(18):2493-2498.
18. Bargou R, Leo E, Zugmaier G, et al.Tumor regression in cancer patients by very low doses of a T-cell-engaging antibody.Science.2008;321:974-977.
19. Topp MS, Gökbuget N, Zugmaier G, et al.Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL.Blood.2012;120(26):5185-5187.
20. Ribera JM, Ferrer A, Ribera J, Genescà E.Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia.Onco Targets Ther.2015;8:1567-1574.
21. Topp MS, Gökbuget N, Stein AS, et al.Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.Lancet Oncol.2015;16(1):57-66.
22. Teachey DT, Rheingold SR, Maude SL, et al.Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.Blood.2013;121(26):5154-5157.
23. Oak E, Bartlett N.Blinatumomab for the treatment of B-cell lymphoma.Expert Opin Investig Drugs.2015;24(5):715-724.
24. Amgen.Phase 2 trial of Blinatumomab in Philadelphia positive/BCR-ABL positive acute lymphoblastic leukemia.Available from: https://clinicaltrials.gov/ct2/show/NCT02000427.Accessed January 19, 2016.
25. ECOG-Acrin Cancer Research Group.Combination chemotherapy with or without Blinatumomab in treating patients with newly diagnosed BCR-ABL-negative B lineage acute lymphoblastic leukemia.Available from: https://clinicaltrials.gov/ct2/show/NCT02003222.Accessed January 19, 2016.
26. Amgen.Phase 3 Trial of Blinatumomab Investigator’s choice of chemotherapy in patients with relapsed or refractory ALL.Available from: https://clinicaltrials.gov/ct2/show/NCT02013167.Accessed January 19, 2016.